Diet, Hepcidin, and Chemotherapy RDI

Launched by GEORGE WASHINGTON UNIVERSITY · Jun 28, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how what women eat before starting chemotherapy for certain types of cancer affects a substance in the body called hepcidin, which can influence how well chemotherapy works. Specifically, the study will focus on women with invasive breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, or endometrial cancer who have not yet received chemotherapy. The researchers want to see if there’s a link between the types of foods women eat—whether they are mostly anti-inflammatory or pro-inflammatory—and the levels of hepcidin in their blood. They will also examine how these hepcidin levels relate to the intensity of chemotherapy doses.

To be eligible for this study, participants must be female, aged 76 or older, and newly diagnosed with one of the specified cancers. They must be scheduled to start chemotherapy at the GW Cancer Center. Women who have had previous blood-related health issues, are pregnant, or have received certain treatments shortly before the study cannot participate. If you join the trial, you will share details about your diet from the month before starting chemotherapy, and you’ll help researchers understand how diet might play a role in treatment effectiveness. This could be an important step towards personalized cancer care.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Have been diagnosed with invasive breast cancer, OR
• • Have been diagnosed with epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, OR
• • Have been diagnosed with endometrial cancer
• • Are chemotherapy-naïve
• • Are scheduled to receive neoadjuvant chemotherapy (or adjuvant chemotherapy following lumpectomy for breast cancer patients) or neoadjuvant/induction chemotherapy for gynecological cancer at GW Cancer Center
• Exclusion Criteria:
• • Prior primary hematological condition that would cause abnormal blood counts (e.g. leukemia)
• • Pregnant at the time of potential enrollment
• • Receipt of erythropoietin-stimulating agents or blood transfusion in the 6 weeks prior to initial testing
• • Women who are cognitively unable to provide a diet history for the month prior to assessment.